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Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, representing
;30% of all cases in western countries. It is an aggressive and molecularly heterogeneous form of
lymphoma, with .18 different subtypes classified by the World Health Organization (WHO).1,2 Primary
refractory disease or relapse DLBCL (rrDLBCL), in which the disease progresses after an apparent
effective treatment or clinical response to standard of care (rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone [R-CHOP]), has long been recognized as a major contributor to the cancer’s
mortality. The 3-year progression-free survival (PFS) in rrDLBCL cases is only 14%.3 Moreover, with the
introduction of personalized and targeted therapies as viable therapeutic options, the appearance of
multiple resistance mechanisms represents a major identified challenge. Thus, understanding the
common features of drug resistance in DLBCL will not only contribute to our understanding of the
leading cause of death in lymphoma, but may also assist in future drug design.
Next-generation-sequencing studies have refined the complexity of DLBCL subtypes and provided new
categorizations of de novo DLBCL.4-7 The genetics of rrDLBCL have been less studied, and only
a limited number of studies have focused on tumor genetic evolution upon relapse by analyzing paired
diagnostic and relapsed biopsies.8-11 In recent years, the majority of sequencing studies in DLBCL have
focused on providing a genetic “lymphopanel” to define the underpinnings of diversity and improve
overall survival (OS) in this disease. We aimed to enhance DLBCL genomic profiling with a relapse-rich
cohort of Nordic DLBCL cases, including 18 serially sampled cases, to contribute substantial
information on progression and relapse.
Methods
Patient samples
A total of 83 cases and 102 biopsies (n [cases] 5 83; b [biopsies] 5 102) of DLBCL were included in
this study. The whole-exome sequencing (WES) cohort consisted of 45 fresh-frozen biopsies from
a Nordic cohort of 37 de novo DLBCL cases with matched normal DNA from peripheral blood, and 11
biopsies without matched normal from 5 patients. Patients were included from Oslo University Hospital
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(OUH) (n5 40; b5 54) and the Helsinki University Central Hospital
Comprehensive Cancer Center (HUCHCCC) in Finland (n 5 2;
b 5 4) (supplemental Tables 1-3; supplemental Figure 1).
A validation cohort using custom panel sequencing of 46 formalin-
fixed paraffin-embedded biopsies was collected at OUH (n 5 35)
or at HUCHCCC (n 5 11) (supplemental Tables 2 and 4;
supplemental Figure 1), excluding cases with low DNA quality.
This study was approved by the Norwegian South Eastern Regional
Ethics Committee (REK 2014/127). The study was performed
according to the Declaration of Helsinki. All patients consented to
written patient information.
WES and variant detection
Genomic DNA from fresh-frozen tissue and EDTA-treated blood
was extracted using the Maxwell 16 DNA isolation automated
magnetic bead instrument (Promega). Library preparation was
carried out using SureSelectXT Human All Exon V5 (Agilent) per the
manufacturer’s instructions at theOUHGenomicsCore Facility, and
whole exome capture and paired-end sequencing was performed
using the Illumina HighSeq 2500 platform (average depth 289X,
range 178-377X for tumor, 126X [range 88-173X] for normal;
supplemental Figure 5). A benchmarked bioinformatics pipeline12
was used to process the sequencing reads and perform somatic
variant calling (supplemental Materials and methods; supplemental
Figure 4).
Copy-number analysis
Copy-number aberration analysis was performed using FACETS13
version 0.5.14. Recurrent copy-number alterations by arm level and
focal, ,50% of the chromosome arm, peaks were analyzed by
GISTIC2.0 (version 2.0.22). Regions of alteration with a q value of
,0.25 were reported as significant. The WES cohort was also
subjected to SNP6.0 analysis using the Affymetrix Genome Wide
SNP6.0 Array platform (Gene Chip lot 4296976).14,15
HLA class I allele and variant detection
POLYSOLVER software (v1; Broad Institute, Cambridge, MA) was
used to infer the HLA class I alleles for each individual, and
POLYSOLVER mutation calling and annotation was performed16
on WES cases with matched normal. Loss of heterozygosity (LOH)
was determined by FACETS13 and POLYSOLVER.
Data analysis
Driver genes were identified with MutSig2CV (Broad Institute)4,17
and OncodriveFM and OncodriveCLUST programs18 (version
2.4.1). Genes with a q value of ,0.1 were selected as harboring
potential driver mutations.17
Clonal structure was inferred with sciClone (version 1.1)19 with
loss-of-heterozygosity information from SNP6.0 array inferred by
ASCAT. We used ClonEvol (https://github.com/hdng/clonevol)
and Fishplot20 (R version 3.4.1) to build tumor phylogenies.
Targeted cancer drugs were identified through the Open Targets
Platform (downloaded 09.19),21 with additional filtering collected
from OncoTree (http://oncotree.mskcc.org/#/home; phenotypes
available upon request). Variant deleterious effect was inferred
through a combined annotation-dependent depletion (CADD)22
phred score of over 10.
Immunohistochemical staining
Immunohistochemical staining (IHC) for class I antigens was
performed applying antibodies against HLA-A (EP1395Y; Abcam)
and b2-microglobulin (B2M) (2M2; Lifespan BioSciences). Details
on IHC staining are provided in supplemental Materials and
methods.
Statistical analysis
GraphPad Prism (Version 8.01) was used to perform an unpaired
2-tailed Student t test with Welch correction, contingency x2, and
the paired Student t test. R (version 3.4.1) was used for linear
regression on time to relapse.
Results and discussion
To address the underlying genomics of acquired and/or intrinsic
resistance in DLBCL, WES was performed on 42 de novo DLBCL
cases consisting of 56 biopsies; 13 cases had available se-
rial biopsies and 34% of all biopsies were taken at relapse
(supplemental Figures 1-4; supplemental Tables 1-3). Custom
targeted sequencing, of 139 genes (supplemental Table 5), was
performed on a second cohort of formalin-fixed paraffin-embedded
samples representing 41 cases of which 23% were relapse
biopsies (supplemental Figures 1 and 3; supplemental Tables 2,
4, and 5).
Given the unique enrichment of relapsed DLBCL in our cohort, we
categorized biopsies as diagnostic DLBCL (from patients who did
not experience relapse), diagnostic rrDLBCL, and relapse biopsies
from rrDLBCL (Figure 1A), and analyzed multiple case sets
stratified by disease subtype, survival, and relapse status. This
approach allowed a comprehensive investigation into the hetero-
geneous subtypes included in our analysis (ABC, GCB, PMBCL,
T-cell/histiocyte-rich; and more, supplemental Tables 1-4) and
exploration based on resistance and progression. Mutation
signatures and overall mutation burden in this Nordic cohort were
similar to previously published western and Chinese cohorts
(median of 125 coding mutations per case; supplemental Figures
5-7).4,8,10,23-27 Using 2 different approaches for cancer driver gene
prediction, we identified 118 potential driver genes including
previously reported genes as well as multiple genes involved in
antigen presentation (supplemental Tables 6 and 7). Four previously
unidentified DLBCL driver genes were discovered: TMEM199,
TBC1D24, IQSEC3, and SYNGR1 (supplemental Tables 6 and 7).
Comparison of driver genes found in diagnostic biopsies from
cases with a durable treatment response and cases that ultimately
went on to relapse revealed an increased number of mutations in
genes involved in antigen presentation, including HLA-A, HLA-B,
CD74, and LILRA4 in the latter set of cases (Figure 1B;
supplemental Figure 8; supplemental Table 6), implicating immune
escape as a notable feature of DLBCL-intrinsic resistance.
In contrast to the initial high sensitivity of DLBCL to standard-of-
care treatment, patients who experience relapse often have
astonishingly aggressive and treatment-refractory disease. We
observed that of the coding variants appearing at relapse, 8
recurrently mutated genes (ie, genes mutated in at least 17% of the
tested relapse biopsies) were not mutated in any diagnostic
pretreatment tumors: CACNA1B, FLRT1, KRAS, LRFN5, MPRIP,
WNT8A, and NR1H2 (Figure 1B; supplemental Figure 12).
However, all are represented in diagnostic biopsies in previously
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studied cohorts. Nevertheless, NR1H2 was reported as exclusively
mutated in relapse biopsies by Morin et al, providing potential
evidence for an association with resistance.8 NR1H2, a nuclear
receptor for LXR-b, is ubiquitously expressed in tissues and is a key
regulator of macrophage function, with a small molecule agonist
currently in clinical trial.28,29
Furthermore, copy-number variation analysis revealed recurrent loss
(either focal or arm level) of a region of chromosome 6p21
containing multiple antigen-presentation and antigen-processing
genes (Figure 1B; supplemental Figure 9). Association of copy-
number variations in 6p21 to clinical outcomes and immune-
privileged site dissemination has been shown previously.30,31 We
detected focal losses of immune-processing genes LGMN and
PSME3, in addition to genes involved in antigen presentation: B2M,
PDIA3, and RFXAP (Figure 1B; supplemental Figure 9). These
findings provide further support for the idea that immune cloaking
may be important in DLBCL resistance.
We quantified variants in HLA-A and revealed an increased
incidence in cases that ultimately relapsed (Figure 2; supplemental
Table 8). Given the highly polymorphic nature of the MHC regions,
we performed further in-depth alignments and investigations into
the mutational prevalence, timing, impact on prognosis, and LOH.
We revealed HLA-A mutagenesis and LOH as a plausible method
of immune evasion in cases that went on to relapse (Figure 2A-C;
supplemental Figure 10; x2 test; P, .02). Given that 2 of our cases
were not treated with R-CHOP–like therapies, we retested this
association without these 2 cases, and it remained significant (x2
test; P , .04). To determine whether these genomic changes in
immune-related genes result in altered protein expression patterns,





























































































































































































































Figure 1. Recurrently altered genes identified in diagnostic and rrDLBCL. Collection of 2 DLBCL cohorts representing various chemo-immunotherapy treatment profiles
allowed for the division into 3 biopsy types prior to genomic alteration analyses by WES (discovery cohort) or by targeted sequencing (validation cohort): Diagnostic DLBCL,
representing initial diagnostic biopsies of patients that go on to have a durable response to RCHOP-like therapies; Diagnostic rrDLBCL, representing initial diagnostic biopsies
of patients that progress or relapse after RCHOP-like therapies; and Relapsed rrDLBCL, representing relapse biopsies of patients who experienced refractory or relapsed
disease. (A) Schematic overview of the sampling procedures for the 3 defined biopsy types of DLBCL. (B) Genes of interest identified by multiple mutation analyses including
the MutSig2CV and IntOgen programs (n [cases] 5 37; b [biopsies] 5 45). Genes of interest have been organized into signaling/pathway categories (gray brackets). Muta-
tions are shown as colored boxes. In cases where a gene had multiple mutations in the same patient, the mutation resulting in the most severe change to the protein structure
is shown. Biopsies are listed horizontally and divided by biopsy type with multiple biopsies from the same patient placed adjacently. The number of mutations for each gene in
the validation cohort is displayed as a histogram on the far right (n 5 41; b 5 46). Genes of interest identified through recurrent copy number alteration analysis (GISTIC2.0)
(n 5 42 in initial analysis, n 5 37 displayed). Multiple genes involved in antigen processing and presentation were identified in the 6p21 cytoband. Each box represents
a gene’s total copy number state. Survival, subtype (including activated B-cell [ABC] like, germinal center B-cell [GCB] like, and primary mediastinal B-cell lymphoma
[PMBCL]), translocation status, age, International Prognostic Index (IPI), and number of extranodal sites for each biopsy are displayed in the bottom rows.
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representing 55 cases of DLBCL pooled from all of our cohorts
(Figure 2D-E). The majority of HLA-A losses were observed in
the rrDLBCL diagnostic and relapse biopsies, but the difference
did not reach statistical significance (Figure 2D; x2 test; P , .1).
B2M expression was variable between the groups (supplemental
Figure 11). Host immunogenetics, particularly HLA haplotypes and
MHC class II variations, has emerged as a potential contributor to
survival in DLBCL and follicular lymphoma patients.32-34 HLA
class I protein deficiencies have been reported in up to 43% of
DLBCL cases.35 We look forward to future investigations to
unravel whether HLA-A mutational and protein status correlate
with neoantigen profiles or the immune microenvironment of
patients.
Thus far, our analyses of the 3 biopsy types have suggested that
immune cloaking may be an intrinsic-resistance mechanism, as
antigen-presentation alterations already exist at diagnosis and may
predict response. Our relapse-rich cohort should provide significant
information in the search for acquired relapse mechanisms and
thereby potentially contribute to development of improved salvage
therapies. Due to clinical practices, serial biopsies are rare, but we
were able to assemble 18 serially sampled cases with correspond-
ing detailed clinical annotations. Patient-wise, we compared
mutations identified in the initial diagnostic biopsy to mutations
identified in the relapse biopsy and integrated the molecular results
with the clinical parameters including biopsy location (supplemental
Figure 13). As time to relapse increased, we observed a strong
trend of decreasing similarity between biopsies representing
evolutionary divergence over time (Figure 3A-B). However, this
observation was independent of lesion location. Leveraging the
availability of matched blood and of copy-number information, we
applied 2 clonality analysis tools (sciClone19 and ClonEvol20) on 7
cases with serial biopsies available (Figure 3C; supplemental
Figures 13 and 14). At each time point, all cases had clones that
contained variants unique to the biopsy at ;50% variant allelic
fraction, thus suggesting 2 different dominant clones at diagnosis
and relapse (Figure 3C; supplemental Figures 13 and 14), with
a substantial overlap of variants between biopsies. This indicates
branched evolution with late divergence of the tumors, and
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Figure 2. Frequent alterations of HLA-A in rrDLBCL. (A) For each biopsy type (diagnostic DLBCL, diagnostic rrDLBCL and relapse rrDLBCL), MHC class I allele
inference for HLA-A was performed using POLYSOLVER. Depicted along the vertical axis are all inferred alleles from the WES with matched normal cohort (n 5 37; b 5 45).
Each box is colored to represent absence, presence, loss, or mutation of each allele in each biopsy. Above the grid, B2M protein-coding variants in each biopsy are shown as
boxes colored by mutation type. (B) Mutation burden in HLA-A per sample by biopsy type. Comparing initial diagnostic biopsies that do (green) or do not (purple) go on to
relapse, the relapsing cases show a significantly higher burden of HLA-A alterations (P , .02, unpaired Student t test with Welch correction). (C) Increased mutational burden
in HLA-A in cases that go on to progress or relapse from R-CHOP–like therapies. Each circle represents a case where analysis was available, each X represents a mutation or
LOH event. (D) Immunohistochemical analysis of HLA-A protein expression in the combined cohort of DLBCL samples from the WES and targeted sequencing cohorts.
Classification into HLA-A negative and positive staining was performed for each biopsy type, n 5 55, b 5 58. (E) Representative images of IHC staining of HLA-A; HLA-A1
and HLA-A2 biopsies obtained on a Nikon Eclipse Ci at 603 objective.




 https://ashpublications.org/bloodadvances/article-pdf/4/9/1859/1727315/advancesadv2019001325.pdf by guest on 11 June 2020
the given therapy and a unique clone, albeit derived from a common
progenitor clone, dominates at relapse (Figure 3C). Founding clones
frequently had alterations in antigen-presentation and -processing
genes such as HLA genes and B2M. In 1 case, P5, multiple variants
in HLA genes were gained throughout the oncogenic progression of
the tumor. However, as in previous investigations, we were unable to
find a recurrent mutation clearly responsible for resistance to
R-CHOP–like therapies. This may suggest that resistance is intrinsic,
or that multiple resistance mechanisms appear in each patient and
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Figure 3. Genomic evolution and druggability. Mutational dynamics and evolutionary divergence in serially sampled rrDLBCL cases. (A) rrDLBCL cases that were serially
sampled between treatment regimens were analyzed to compare the genomic alterations before and after treatment. Variants were classified as shared (present in both
biopsies) or private (present in only 1 biopsy). For each case, the percent of shared variants between the diagnostic and relapse biopsies was calculated and plotted against
time between biopsies. Biopsy site location and type of sequencing (WES or targeted) were integrated as the color and shape of each point, respectively. A negative linear correlation
between genetic similarity and time between biopsies was observed (P , .00016). (B) Below the plot, a schematic example is shown: over time, a founding clone (white circle with black
founding mutations) evolves into the clones present at diagnosis (green with orange private mutations) and at relapse (blue, with red private mutations). Clonal evolutionary analysis and
identification of druggable alterations was performed, n 5 18. (C) Schematic images of representative biopsies are shown with inferred clonal population percentages and branching
evolutionary trees. Clinical information including subtype and treatment are displayed. To the right of each case, “fish plots” illustrate the clonal architecture of the 2 tumor biopsies,
inferred from clonal fractions of mutation clusters and response to treatment. Mutations in genes of interest are shown in clones when they occurred, with genes involved in antigen
presentation highlighted in red. (D) Druggable somatic mutations were identified using the Open Targets Platform, and oncogenic potential was estimated using CADD. Histogram of
mutation counts of those variants identified as druggable and oncogenic in serially biopsied cases colored by shared vs private status, relapse vs diagnostic (n 5 18, b 5 37) paired
Student t test (n 5 16 (excluded relapse-relapse serial pairs), P 5 .0221). (E) Illustrative branched evolutionary trees representing founding clone mutations (gray trunk) and mutations
private to diagnostic biopsies and relapsed biopsies (green and blue, respectively). Druggable mutations in genes of interest are displayed.
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Given the strong similarities between diagnostic and relapse
biopsies and the observed evolutionary divergence with time, we
sought to understand whether relapse sampling advances our
understanding of treatment options enough to warrant rebiopsies.
We assessed the evolutionary timing of mutations in druggable targets.
There were amedian of 23mutations per biopsy in genes targetable by
known antineoplastic drugs as listed in the Open Targets Platform.21
To incorporate the functional impact of each variant on driving cancer,
we analyzed all druggable variants using CADD22 (Figure 3D-E).
Private variants in druggable genes were found more frequently in
relapse biopsies than in initial diagnostic biopsies (Figure 3D; P ,
.0221). Although our results indicate that relapse sampling is important
for guiding treatment, obtaining relapse biopsies can present ethical
and practical issues for clinicians. Therefore, sampling of the peripheral
blood for circulating tumor DNA or circulating tumor cells may provide
an alternative investigational route for relapse sampling.36-38
Two of the previous studies on serially sampled rrDLBCL cases
revealed a novel increase in mutations associated with the NF-kB
pathway and that immune surveillancewas disrupted by indels and copy
number variations in CD58 and B2M.23 In contrast, in our paired
samples, these alterations were seen in both the diagnostic and relapse
biopsies. Our results suggest that immune-surveillance targeting also
occurs at diagnosis, and should be taken into consideration when
making clinical decisions on the use of the growing arsenal of immune
therapies. Theoretically, these patients may be able to develop
resistance to checkpoint blockade and neoantigen therapy, but may
be sensitive to engineered immune therapies such as chimeric antigen
receptor–T-cell therapies and NK-cell therapies. CD19-engineered
chimeric antigen receptor T cells have shown long-term durable
response rates in up to 58% in rrDLBCL.39-43More broadly, our findings
yield insight into the development of resistance in DLBCL, and highlight
antigen processing and presentation as key targets for genomic
aberrations in rrDLBCL cases. Moreover, our findings provide a clear
investigational route into the effect of HLA-A mutations on relapse
status in future clinical correlative studies.
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